Precigen director acquires 71839 shares via RSUs
PRECIGEN, INC. director Jeffrey B. Kindler received common stock through the vesting of previously granted restricted stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PRECIGEN, INC. director Jeffrey B. Kindler received common stock through the vesting of previously granted restricted stock units. On March 13, 2026, 71839 RSUs vested in full, converting into 71839 shares of common stock at no exercise price. Following this compensation-related transaction, he directly holds 202100 shares of Precigen common stock, with no reported open-market purchases or sales and no remaining derivative holdings in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 71,839 | $0.00 | $0.00 |
| Exercise | Common Stock | 71,839 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
- F2. The RSUs vested in full on March 13, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Precigen (PGEN) disclose for Jeffrey B. Kindler?
How many Precigen (PGEN) restricted stock units vested for the director?
What does the RSU vesting mean for Precigen (PGEN) director compensation?
AI-generated analysis. How Rhea-AI works. Not financial advice.